TP53 and cancer: The compound showed anti-MDR effects with relative reversal (RR) values of 0.5, 0.73, and 0.86 in HCT116 (p53−/−), CEM/ADR5000, and U87MG.ΔEGFR glioblastoma cell lines, respectively, and a collateral resistance (CR) value of 0.22 in MDA-MB-231-BCRP cancer cell [146].